SCHEMBL19631671

SCHEMBL19631671

CCN(c1ccc(S(=O)(=O)N(Cc2ccc(OC)cc2OC)c2ncns2)cc1Cl)[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 4/20 0.41
GPR119 Q8TDV5 4/20 0.37
STS P08842 2/20 0.36
BMP1 P13497 1/20 0.36
EPHX2 P34913 1/20 0.36
SCN9A Q15858 3/20 0.35
P2RX3 P56373 1/20 0.35
NR1D1 P20393 1/20 0.35
MAPT P10636 1/20 0.34
SCN1A P35498 2/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29447421 1.00 SCN8A (0.41) SCN8AGPR119STSBMP1EPHX2
SCHEMBL19627619 0.94 SCN8A (0.41) SCN8AGPR119STSBMP1EPHX2
SCHEMBL19631492 0.93 SCN8A (0.41) SCN8AGPR119STSEPHX2SCN9A
SCHEMBL29447387 0.93 SCN8A (0.41) SCN8AGPR119STSEPHX2SCN9A
SCHEMBL19613015 0.92 SCN8A (0.45) SCN8ASCN9ASCN1AALDH1A1KMT2A
SCHEMBL19613016 0.92 SCN8A (0.45) SCN8ASCN9ASCN1AALDH1A1KMT2A
SCHEMBL19627614 0.86 SCN8A (0.41) SCN8AGPR119STSBMP1EPHX2
SCHEMBL19631669 0.85 STS (0.39) SCN8AGPR119STSBMP1SCN9A
SCHEMBL29447419 0.85 STS (0.39) SCN8AGPR119STSBMP1SCN9A
SCHEMBL19614244 0.84 SCN8A (0.44) SCN8ASCN9ASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 US disclosed
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-05-26 US disclosed
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2019-06-27 US disclosed
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2019-04-02 US disclosed
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 US disclosed
WO-2017201468-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885GPR119 1866/4885STS 181/4885
US-10246453-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 14/4885GPR119 1866/4885STS 181/4885
US-20170334902-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885GPR119 1866/4885STS 181/4885
US-10662184-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN8A 10/4885GPR119 1879/4885STS 162/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 14/4885GPR119 1866/4885STS 181/4885
US-20190194184-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN8A 10/4885GPR119 1879/4885STS 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.